GLP-1 Drugs and Eating Disorders: What Prescribers and Patients Should Know

The intersection of GLP-1 drugs and eating disorders is one of the most clinically complex areas in the entire GLP-1 literature — and one of the most important to get right, given the population of people with obesity who also have eating disorder histories.

This article awaits medical-reviewer signoff.

The fundamental tension

GLP-1 drugs suppress appetite — powerfully, in most patients. For a patient with food insecurity or a history of food restriction, that suppression can interact with disordered eating patterns in ways that are harmful.

Conversely, for patients whose eating disorder manifests as loss-of-control eating or reward-driven hyperphagia, the same mechanism might be therapeutic.

Whether a GLP-1 drug helps or harms in the context of disordered eating depends entirely on the type of eating disorder and its current state.

Restrictive eating disorders: the high-risk scenario

Anorexia nervosa is characterised by restriction of food intake below physiological need, intense fear of weight gain, and distorted body image. It has the highest mortality rate of any psychiatric disorder.

Atypical anorexia nervosa meets all anorexia criteria except the patient is at or above a "normal" weight — which means many atypical anorexia patients may have been recommended GLP-1 drugs without the treating prescriber being aware of the underlying disorder.

The harm mechanism: GLP-1 appetite suppression in a patient with a restrictive eating disorder provides a pharmacological tool for restriction. The hunger that normally creates pressure toward eating — however uncomfortable for the patient — provides some physiological safeguard against dangerous levels of restriction. GLP-1 therapy removes that safeguard.

Clinical reports include patients with undiagnosed atypical anorexia who started GLP-1 therapy for weight management and experienced rapid dangerous weight loss, reinforced restriction, and medical complications because the prescriber was unaware of the underlying disorder.

Clinical guidance: Active restrictive eating disorders are generally considered a contraindication to GLP-1 therapy. The National Eating Disorders Association has specifically flagged this concern. Eating disorder history screening at GLP-1 initiation is a clinical best practice.

ARFID (Avoidant/Restrictive Food Intake Disorder): A separate condition characterised by limited food range and low intake (not fear-of-weight-gain driven). GLP-1 appetite suppression can make ARFID patients less likely to eat the limited foods they already accept — worsening nutritional status. High risk without appropriate ARFID specialist co-management.

Binge-eating disorder: the more nuanced picture

Binge-eating disorder (BED) is characterised by recurring episodes of eating large amounts of food in a discrete period with a sense of loss of control, without the compensatory behaviours (purging) of bulimia nervosa. BED is the most common eating disorder in the United States.

The therapeutic mechanism possibility: GLP-1 receptors in the mesolimbic dopamine system modulate reward salience — how compelling food (and other stimuli) feel. In BED, loss-of-control eating episodes appear linked to dysregulated dopaminergic reward signalling in response to food cues. GLP-1 agonism may reduce the reward salience of binge trigger foods.

Emerging evidence:

• Case series and observational data suggest some BED patients experience reduced binge frequency on GLP-1 therapy
• A clinical trial (NCT05910476) was studying semaglutide for BED specifically as of 2026
• The same mechanism being studied for alcohol use disorder (GLP-1 reducing alcohol reward) is theoretically relevant for BED's reward-pathway dysregulation

Current clinical status: GLP-1 therapy for BED is not yet standard of care. First-line BED treatment remains: CBT-based psychotherapy and, pharmacologically, lisdexamfetamine (Vyvanse), topiramate, or antidepressants. GLP-1 use in BED should involve eating disorder specialist co-management given the complexity.

Bulimia nervosa

The concerns: Purging (self-induced vomiting) combined with GLP-1 therapy raises concerns about:

• Electrolyte abnormalities from purging + GI effects of GLP-1
• Medication absorption (vomiting after injection is not a GLP-1 absorption issue since it's subcutaneous, but oral GLP-1s would be affected)
• Reinforcing compensatory behaviours in a disorder driven by restriction-binge-purge cycles

Limited specific evidence exists for GLP-1 use in bulimia nervosa. This is high-risk territory requiring specialist co-management.

Clinical recommendations

Screening at initiation: Ask about past and current eating disorder diagnoses, history of significant restriction, binge eating, or purging. This is particularly important for patients who have previously had very restrictive diets, bariatric surgery consideration, or a history of adolescent dieting behaviours.

Consultation/co-management: For any patient with current or past eating disorder history, eating disorder specialist or psychologist consultation before or concurrent with GLP-1 initiation is best practice.

Close monitoring: Patients with eating disorder histories who do proceed with GLP-1 therapy require close follow-up — not just for weight, but for eating patterns, restriction behaviours, and mental health status.

Weight restoration priority: For patients with anorexia nervosa or significantly low weight, weight restoration is the clinical priority. GLP-1 drugs that reduce appetite and facilitate further weight loss are contraindicated in this context.

Editorial note: This article awaits medical-reviewer signoff and eating disorder specialist review. Eating disorder management is a highly specialised clinical domain. This article is informational; individual clinical decisions require eating disorder specialist involvement.